Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SOAT2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | SOAT2 Lentivirus Particles Full-length ORF, CMV promoter, Puromycin selection. For stable HepG2/HEK293 cell lines. Endotoxin <1 EU/µg. Preserves native ER membrane folding for multipass targets. |
View SOAT2 Products |
| Antigen | SOAT2 Recombinant Protein (Partial/Truncated & Full-Length options) HEK293 expressed, Sequence Verified. High purity (>85-95%). Options include truncated domain for epitope mapping and full-length detergent-solubilized preparation for ELISA. |
View SOAT2 Products |
| Benchmark Ab | Anti-SOAT2 Biosimilar Recombinant positive control for Western blot, IHC, and target engagement studies. |
View SOAT2 Products |
| Validator | SOAT2 siRNA Set (3 unique sequences) For knockdown verification and target-specificity confirmation in cellular assays. HPLC purified. Negative control scrambled siRNA included. |
View SOAT2 Products |
| Related Target: SOAT1 | SOAT1 (ACAT1) Protein & Lentivirus Critical for selectivity counter-screening to avoid off-target toxicity. Sequence-verified ortholog. |
View SOAT1 Products |
| Related Target: PCSK9 | PCSK9 Recombinant Protein (ECD-Fc, >95% purity) Synergistic target for hypercholesterolemia and combination therapy research. |
View PCSK9 Products |
| Related Target: LDLR | LDLR Recombinant Protein Cholesterol uptake pathway partner for combinatorial studies. |
View LDLR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SOAT2 vs SOAT1 Selectivity Screening | Matched pair of SOAT1 and SOAT2 proteins expressed in identical HEK293 systems; Sequence Verified; enables precise SOAT2/SOAT1 IC50 ratio. |
| Multipass Membrane Conformation | Lentivirus-based stable cell lines preserve native ER membrane topology; Suitable for cholesterol esterification (BODIPY-cholesterol) assays. |
| Lack of Positive Controls / False Positives | Recombinant benchmark antibodies and validated siRNA included for target engagement confirmation. |
| Cross-species Evaluation | Human/Mouse/Cynomolgus SOAT2 ortholog proteins available with >95% purity and sequence verification by mass spec. |
| Cholesterol Loading Assays | Compatible with fluorescent cholesterol analog uptake readouts in lentivirus-transduced cells. |
Live SOAT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ ACAT2 Synonym Trials
- ➤ Latest Resistance & Mechanism Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for SOAT2 (ACAT2) therapeutics is intensifying, with a strategic pivot from pan-ACAT inhibitors (e.g., pactimibe, avasimibe) to highly selective inhibitors and genetic medicines (siRNA/ASO). First-generation pan-inhibitors failed due to adrenal toxicity from SOAT1 inhibition and limited efficacy. Current R&D focuses on exclusive SOAT2 blockade to avoid disrupting glucocorticoid synthesis and peripheral cholesterol homeostasis. Key indications include Non-Alcoholic Steatohepatitis (NASH/MASH), Hepatocellular Carcinoma (HCC), severe hypercholesterolemia, and emerging interest in Alzheimer's disease (via cholesterol compartmentalization affecting APP processing). The next wave of innovation involves:
- Sub-cellular cholesterol trafficking modulation
- SOAT2-independent compensatory pathway analysis (bypass mechanisms)
- Hepatocyte-specific delivery (GalNAc conjugates, liver-targeted small molecules) to minimize systemic exposure
- Combination therapy with statins, PCSK9 inhibitors, or GLP-1R agonists for synergistic metabolic control
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective) | AstraZeneca, Daiichi Sankyo, Pfizer, Academic Spin-offs | Atherosclerosis, FH, NASH | SOAT1/SOAT2 Selectivity Panel; Lentivirus stable cell lines for enzyme kinetics |
| Small Molecule (CNS-penetrant) | Academic consortia, Biotech | Alzheimer's Disease | BBB-Permeable Cell Model (Lentivirus-stable hCMEC/D3 lines) |
| Antisense Oligonucleotide | Ionis Pharmaceuticals (historical) | NASH, Severe Hypercholesterolemia | SOAT2 Protein Detection (high-specificity antibodies/antigens) |
| siRNA / Genetic Modulation | Alnylam (preclinical) | Refractory Lipid Disorders, Metabolic Liver Disease | Knockdown Validation (validated siRNA sets, qPCR/Western) |
| Targeted Degradation | Early-stage Innovators | Hepatocellular Carcinoma | Degradation Kinetics (Lentivirus for overexpression in HCC lines) |
Key Assay Challenges and TarMart Advantages
- Selectivity: Counter-screen against SOAT1 using matched protein pairs. TarMart provides HEK293-expressed, sequence-verified SOAT1 and SOAT2 for IC50 ratio determination.
- Membrane Protein Handling: Lentivirus-mediated stable cell lines preserve native ER conformation; recombinant proteins are detergent-solubilized for in vitro assays.
- Target Engagement: Validated siRNA set ensures genetic knockdown confirmation alongside pharmacological inhibition.
- Cross-species Translation: Human/Mouse/Cyno orthologs support preclinical PK/PD modeling.